

Special Issue

Antimicrobial Agents Used in Intensive Care Unit

Message from the Guest Editor

Antimicrobial agents constitute a fundamental part of medical treatment. Without them, the risk of bacterial or fungal infections would be intolerably high. However, antibiotic resistance is now a modern medicine threat all around the globe. To make matters worse, critically ill patients in ICUs often suffer from pathophysiological changes that affect PK/PD target attainment and result in toxicity or under-dosing/resistance. Despite the increase in the application of therapeutic drug monitoring to adjust the dosing therapy for ICU patients, pitfalls in antimicrobial therapy are still a major concern. This Special Issue seeks manuscripts that discuss/describe any treatment approach to overcome resistance, such as new methods for drug monitoring, discovery of new antimicrobial agents, or improvement in the stability of antimicrobial agents. In addition, manuscripts that enhance our understanding about this topic and help improve the antimicrobial therapy in ICU are welcome. Keywords: Infection; Antimicrobial Therapy; Toxicity; Resistance; Therapeutic Drug Monitoring; Personalized Medicine; Intensive Care Units; Critically Ill patients

Guest Editor

Dr. Nahed El-Najjar

Department of Pharmacology and Toxicology, American University of Beirut, Beirut, Lebanon

Deadline for manuscript submissions

closed (31 December 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/67017

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)